AI assistant
Royalty Pharma plc — Director's Dealing 2025
May 14, 2025
30286_dirs_2025-05-14_a3237c92-0da7-40ef-8102-39b580b93544.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Royalty Pharma plc (RPRX)
CIK: 0001802768
Period of Report: 2025-05-13
Reporting Person: HODGSON DAVID C (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2025-05-13 | Class A Ordinary Shares | A | 7614 | — | Acquired | 33328 | Direct |
Footnotes
F1: Reflects an award of restricted stock units under the Issuer's 2020 Independent Director Equity Incentive Plan (the "Plan") that is generally scheduled to vest 100% on the earlier of (i) the one-year anniversary of the grant date and (ii) the date of the annual meeting of the Issuer's shareholders in the first calendar year following the grant date, subject to the terms of the Plan and the applicable award agreement thereunder. The restricted stock units granted to the reporting person are held by him solely for the benefit of General Atlantic Service Company, L.P. The reporting person disclaims beneficial ownership of the restricted stock units in the underlying shares.